Equip DNA Info Lab · Revisió editorial · · 6 min de lectura
23andMe Raw Data Analysis: What You Can (and Cannot) Learn
What can a 23andMe raw data analysis tell you? Research associations from the GWAS Catalog, pharmacogenomics (drug response), trait associations and some carrier-status hints — all from common variants. It cannot give a diagnosis, detect rare mutations not on the chip, or predict your future. Here is the honest scope.
Once you have your raw file, the useful question is not "what can I run" but "what can the result actually mean". Consumer microarray data is powerful for some questions and useless for others. Here is the honest boundary.
What you CAN learn
- Research associations — which of the variants studied for common conditions (type 2 diabetes, cardiovascular, Alzheimer's, depression and more) are in your file, each with the trait its study measured and the effect it reported, from the GWAS Catalog. We do not add them into a score: see our methodology for why.
- Pharmacogenomics — how your genotype may affect response to common drugs (warfarin, statins, clopidogrel, codeine, SSRIs, metformin), from PharmGKB. For all of them except metformin there are also CPIC clinical guidelines.
- Trait associations — well-studied, low-stakes traits like lactose tolerance, caffeine intake (linked to variants near CYP1A2, the gene for the enzyme that breaks caffeine down), or the ACTN3 "sprint" variant.
- Carrier hints — some ClinVar-flagged variants that are on the chip. Not a full carrier screen, but a starting signal.
What you CANNOT learn
- A diagnosis. An association measured across a study population is not a verdict about you. Carrying the studied allele is not disease; not carrying it is not safety.
- Rare private mutations. If a variant was not on the chip (~99.98% of the roughly 3 billion nucleotides in your genome are not), it simply is not in the file. A "clear" result never rules out a rare mutation.
- Your full genome. A chip reads only chosen positions: 23andMe's current (v5) chip is built on about 654,000 preselected variants plus about 50,000 custom ones. For everything else you need whole-genome sequencing.
- The future. Genetics is one input among many — lifestyle, environment and chance dominate most outcomes.
The ancestry caveat
In the GWAS Catalog, about 86% of the participants in discovery studies published from 2005 to 2018 were of European ancestry. If your ancestry is different, the effects they report may not transfer with the same magnitude — an honest analysis flags this rather than hiding it. Treat non-European results with extra caution.
How accurate is it?
For common variants the genotyping itself is highly accurate: in a comparison with sequencing in 49,908 UK Biobank participants, chip calls matched sequencing more than 99% of the time, and 23andMe reports over 99% accuracy and reproducibility for the variants in its FDA-authorised reports. Very rare variants are the exception: in the same study only 16% of the chip's heterozygous calls at variants rarer than 1 in 100,000 were confirmed by sequencing, so a rare finding in a raw file needs clinical confirmation. The rest of the uncertainty is in interpretation: effect sizes come from population studies with confidence intervals, and how much of an area your file covers varies (a category the chip matched at 40 positions was checked against more research than one matched at 4 — which is a statement about your file, not about how much to trust either result). Good tools show you the coverage and the source for every match, and no aggregate figure they cannot defend.
How to run the analysis
You can do it by hand — look up individual rsids in SNPedia and the GWAS Catalog — or upload the whole file to a tool that cross-references it automatically and explains each result, with its limits, in plain language.
Frequently asked questions
Can 23andMe raw data diagnose a disease?▼
No. It reports associations measured across research populations, not a clinical diagnosis and not a prediction about you. Anything concerning should be confirmed with a doctor and, where appropriate, clinical-grade testing.
Will an analysis find every genetic condition I might carry?▼
No. It only covers variants on the chip (~0.02% of the genome), and chip calls for very rare variants are often wrong. A reassuring result never rules out a rare mutation that was not tested, and a rare finding needs clinical confirmation.
Does non-European ancestry change what the analysis can say?▼
For the GWAS research areas, yes: those studies over-represent European-ancestry participants, so an effect measured there may be different, or absent, in your population. It does not apply the same way to the clinically-reviewed ClinVar findings or the drug annotations, which are not filtered by ancestry. Interpret the research areas with caution.
Do I need whole-genome sequencing instead?▼
Only if you need rare-variant coverage. For common-variant risk, pharmacogenomics and traits, microarray raw data is more than enough.
Ja tens el teu fitxer d'ADN brut?
Explora les coincidències, explicacions, límits i fonts disponibles per al teu fitxer.
Related articles
Aquest article té finalitats exclusivament educatives i no constitueix consell mèdic, diagnòstic ni tractament. Consulta sempre un professional sanitari per a decisions sobre la teva salut.